Cariprazine Capsules bulk supplier for pharma manufacturers

Cariprazine Capsules 1.5 mg, 3 mg, 4.5 mg, 6 mg Suppliers & Bulk Manufacturers

Available Forms: Oral Capsules

Available Strengths: 1.5 mg, 3 mg, 4.5 mg, 6 mg

Reference Brands: Vraylar®(US); Reagila®(EU)

Cariprazine is an atypical antipsychotic that works as a partial agonist at dopamine D2 and D3 receptors, with a higher affinity for D3, and serotonin 5-HT1A receptor partial agonism, along with 5-HT2A receptor antagonism. This receptor activity helps balance dopamine and serotonin levels in the brain. Cariprazine capsules are used to treat schizophrenia, bipolar I disorder (manic or mixed episodes), and as an adjunctive treatment for major depressive disorder (MDD). Its unique D3 activity may offer cognitive and mood-related benefits with a favorable side effect profile.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description:

Cariprazine capsules are FDA-approved in the U.S. for schizophrenia, bipolar I disorder (manic/mixed episodes), and as adjunctive therapy for major depressive disorder (MDD). In the EU, they are approved under the brand name Reagila for schizophrenia via centralized EMA procedures. Regulatory requirements include GMP-compliant manufacturing, robust clinical data, and safety documentation addressing extrapyramidal symptoms (EPS), akathisia, and metabolic effects. U.S. labeling must follow FDA guidance with boxed warnings for elderly dementia-related psychosis. EMA approval mandates detailed pharmacovigilance systems and Risk Management Plans (RMPs). To explore dossier-ready Cariprazine capsules, visit Pharmatradz.com — your global B2B pharma sourcing partner.

Cariprazine Capsules — third party manufacturing & bulk supply

Cariprazine Capsules 1.5 mg, 3 mg, 4.5 mg, 6 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Cariprazine Capsules is supplied as Oral Capsules — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Cariprazine Capsules listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Cariprazine Capsules →

Back to Listing

Frequently Asked Questions

Cariprazine is used to treat psychiatric conditions such as schizophrenia and bipolar disorder. It helps manage symptoms like hallucinations, delusions, mood swings, and agitation, improving overall mental stability and daily functioning.

Cariprazine is a synthetic pharmaceutical compound that acts as a dopamine D3/D2 and serotonin 5-HT1A receptor partial agonist. It is manufactured under controlled pharmaceutical processes to ensure consistent therapeutic effects and safety.

Cariprazine is marketed under the brand name Vraylar in the United States and other regions.

Cariprazine (Vraylar) is manufactured and marketed by Recordati Pharmaceuticals, with distribution in multiple countries through authorized partners.

The generic name is Cariprazine.

The most recognized brand name is Vraylar.

Cariprazine is manufactured in regulated pharmaceutical facilities that comply with international quality and safety standards, including sites in the United States, Europe, and other approved markets.